- Home
- MPLT vs AKBA Comparison
MPLT vs AKBA Comparison
Compare MPLT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPLT
- AKBA
- Stock Information
- Founded
- MPLT 2018
- AKBA 2007
- Country
- MPLT United States
- AKBA United States
- Employees
- MPLT N/A
- AKBA N/A
- Industry
- MPLT Biotechnology: Pharmaceutical Preparations
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- MPLT Health Care
- AKBA Health Care
- Exchange
- MPLT Nasdaq
- AKBA Nasdaq
- Market Cap
- MPLT 700.6M
- AKBA 729.1M
- IPO Year
- MPLT 2025
- AKBA 2014
- Fundamental
- Price
- MPLT $16.20
- AKBA $2.12
- Analyst Decision
- MPLT
- AKBA Strong Buy
- Analyst Count
- MPLT 0
- AKBA 6
- Target Price
- MPLT N/A
- AKBA $6.25
- AVG Volume (30 Days)
- MPLT 780.2K
- AKBA 4.5M
- Earning Date
- MPLT 11-28-2025
- AKBA 11-10-2025
- Dividend Yield
- MPLT N/A
- AKBA N/A
- EPS Growth
- MPLT N/A
- AKBA N/A
- EPS
- MPLT N/A
- AKBA N/A
- Revenue
- MPLT N/A
- AKBA $203,733,000.00
- Revenue This Year
- MPLT N/A
- AKBA $43.91
- Revenue Next Year
- MPLT N/A
- AKBA $32.09
- P/E Ratio
- MPLT N/A
- AKBA N/A
- Revenue Growth
- MPLT N/A
- AKBA 16.75
- 52 Week Low
- MPLT $15.00
- AKBA $1.52
- 52 Week High
- MPLT $20.86
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- MPLT N/A
- AKBA 31.30
- Support Level
- MPLT N/A
- AKBA $2.07
- Resistance Level
- MPLT N/A
- AKBA $3.19
- Average True Range (ATR)
- MPLT 0.00
- AKBA 0.16
- MACD
- MPLT 0.00
- AKBA -0.09
- Stochastic Oscillator
- MPLT 0.00
- AKBA 4.46
About MPLT MapLight Therapeutics Inc. Common Stock
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.